Latest From Harbour BioMed
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.
The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Parent & Subsidiaries
- Harbour BioMed
- Senior Management
Jingsong Wang, MD, PhD, CEO
Mai-Jing Liao, PhD, SVP, Head, Bus. Dev.
Xiaoxiang Chen, MD, EVP, Head, Clin. Dev. & Reg. Science
- Contact Info
866 Halei Rd., Ste. 311
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.